EU/3/19/2143:

Lurbinectedin

Table of contents

Overview

On 26 February 2019, orphan designation (EU/3/19/2143) was granted by the European Commission to Pharma Mar S.A., Spain, for lurbinectedin for the treatment of small cell lung cancer.

Key facts

Active substance
Lurbinectedin
Intented use
Treatment of small cell lung cancer
Date of designation
26/02/2019
Orphan designation status
Positive
EU designation number
EU/3/19/2143

Sponsor's contact details

Pharma Mar S.A.
Avda. de los Reyes, 1 
Pol. Ind. La Mina 
28770 Colmenar Viejo 
Madrid 
Spain
Tel. + 34 9182 34553
E-mail: abirigaray@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating